IDO1 and neoplasm: Based on these promising results, another three clinical trials (NCT01543464, NCT02077114, and NCT03047928) were performed to combine nivolumab or ipilimumab or chemotherapy with IDO peptide to study the synergistic anti-tumor effects [83].